Nestec S.a.

Csl Behring Ag

Beth Israel Deaconess Medical Center, Inc.

Universitaet Bern

Nectec S.a.

Kenta Biotech Ag

Adrian Zuercher

Annick Mercenier

Sebastien Holvoet

Sylvia Miescher

Marie-Claire Fichot

Martin A Imboden

Anurag Singh

Cédric Pierre Vonarburg

Blaise Corthésy

Marius Loetscher

Ciaran Kelly

Michael P Horn

Alois B Lang

Sonja Christina Lueer

Alexander Schaub

Christoph Aebi

Marietta Weiss

Sandra Wymann

Martin Spycher

Xinhua Chen

Stéphanie Longet

Cedric Pierre Vonarburg

Stephanie Longet

Blaise Corthesy

Sébastien Holvoet

The invention relates to methods for preparing compositions comprising secretory-like immunoglobulin, in particular secretory-like IgA and/or secretory-like IgM, and compositions obtainable by the methods.

Compositions comprising secretory-like immunoglobulins

The invention relates to compositions and methods to prevent enteric infection in a subject at risk of such infection. In particular, the invention relates to the prevention of recurrence of infection by

Prevention of infection

A composition comprising specificstrains is provided for reducing the symptoms of allergies originating from food, respiratory or contact allergens. Preferably the composition reduces symptoms of allergies (secondary prevention) while also able to reduce sensitization (primary prevention).

[object Object]

The invention relates to compositions comprising immunoglobulin for use in the treatment of mucositis by topical application. In particular, the invention relates to compositions comprising J chain-containing IgA and secretory component for the treatment of mucositis.

Treatment of mucositis with immunoglobulin

A complete nutritional composition comprisingstrains or probiotic is provided for reducing the symptoms of allergies originating from food allergens in young children or infants. Preferably the composition reduces symptoms of allergies (secondary prevention) and also reduces sensitization (primary prevention). The composition comprises a probiotic of the genus

A nutritional composition comprising a partially hydrolyzed milk protein having a degree of hydrolysis between 15 and 25% and 50 to 1000 nanograms of TGF-&#x3b2; per 100 ml of ready to consume composition and methods for the primary prevention of allergic reactions to newly introduced dietary protein at weaning and the prevention of development of atopic diseases in a young mammal at weaning comprising feeding to the young mammal a therapeutic amount of the composition are disclosed.

Prevention of allergy at weaning

A complete nutritional composition comprisingstrains or probiotic is provided for reducing the symptoms of allergies in different groups of patients such as allergies originating from food allergens in young children or infants and respiratory allergens in children, adults and household pets. Preferably the composition reduces symptoms of allergies (secondary prevention) while not significantly affecting sensitization (primary prevention). The composition comprises a probiotic of the genus

A complete nutritional composition comprising polyphenols is provided for reducing the symptoms of allergies originating from food allergens in young children or infants. Preferably the composition modulates the secondary prevention of allergies while not affecting significantly the primary prevention. The composition comprises an apple extract.

Nutritional composition comprising an apple extract and reducing food allergy symptoms, especially in children

A nutritional composition comprising a partially hydrolysed milk protein having a degree of hydrolysis between 15 and 25% and 50 to 1000 nanograms of TGF-&#x3b2; per 100 ml of ready to consume composition and methods for the primary prevention of allergic reactions to newly introduced dietary protein at weaning and the prevention of development of atopic diseases in a young mammal at weaning comprising feeding to the young mammal a therapeutic amount of the composition are disclosed.

The present invention relates to a human monoclonal antibody specific for the serotype IATS O11 of, a hybridoma producing it, nucleic acids encoding it, and host cells transfected therewith. Further, the present invention relates to methods for producing said monoclonal antibody. In addition, the present invention relates to pharmaceutical compositions comprising at least one antibody or at least one nucleic acid encoding said antibody.

Growing community of inventors

Bern, Switzerland

Adrian Zuercher